Article

CBER Recall of Hepatitis A Vaccine

Author(s):

BioPharm International Editors

CBER Recall of Hepatitis A Vaccine, Inactivated (VAQTA) Packaged in single-dose prefilled syringes, posted 10 December 2001

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Related Content
airborn virus floating aroud in droplets on blue sky background | Image Credit: ©the_lightwriter -stock.adobe.com
August 9th 2025

New Technologies for Viral Clearance

Cynthia A. Challener
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
August 9th 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
August 9th 2025

European TICC group, Normec, Gains Foothold in US Market with Three Strategic Acquisitions

Feliza Mirasol
Mastering Antibody-Drug Conjugates
August 9th 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
Doctor or scientist shows a vial of genetic agent as a vaccine or therapy against Corona or Covid-19 as a symbolic image | Image Credit: © Dan Race - stock.adobe.com
August 9th 2025

Reaction and Fallout as HHS ‘Winds Down’ mRNA Vaccine Development, Canceling $500 Million in Projects

Patrick Lavery
Hourglass illuminated in red and blue on a black background | Image credit: ©Juri – Stock.Adobe.com
August 9th 2025

Time-to-Market Pressures Are Influencing Downstream Processing Innovations

Cynthia A. Challener
© 2025 MJH Life Sciences

All rights reserved.